Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity

Oncology Reports

Volumn 24, Issue 6, 2010, Pages 1621-1627

  Yamanegi, Koji ^a   Yamane, Junko ^a   Kobayashi, Kenta ^a   Kato Kogoe, Nahoko ^a   Ohyama, Hideki ^a   Nakasho, Keiji ^a   Yamada, Naoko ^a   Hata, Masaki ^a   Nishioka, Toshihiro ^a   Fukunaga, Satoru ^a   Futani, Hiroyuki ^a   Okamura, Haruki ^a   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

HDAC inhibitor; MIC; Osteosarcoma; Soluble MIC; VPA

Indexed keywords

HISTONE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MICA; PROTEIN MICB; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; ARTICLE; CELL STIMULATION; CELL SURFACE; DRUG EFFECT; HUMAN; HUMAN CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

EID: 78649396020     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00001026     Document Type: Article

References (18)

1. Waldhauer I and Steinle A: NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943, 2008.
2. Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958, 2008.
3. Jinushi M, Takehara T, Tatsumi T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S and Hayashi N: Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43: 1013-1020, 2005.
4. Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
5. Glozak MA and Seto E: Histone deacetylases and cancer. Oncogene 26: 5420-5432, 2007.
6. Skov S, Pedersen TM, Andersen L, Straten PT, Woetmann A and Ødum N: Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65: 11136-11145, 2005.
7. Armeanu S, Bitzer M, Lauer UM, et al: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005.
8. Diermayr S, Himmelreich H, Durovic B, et al: NKG2D ligand expression in AML increase in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK cell lines with single KIR-HLA-class I specificities. Blood 111: 1428-1436, 2008.
9. Schmudde M, Braun A, Pende D, et al: Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett 272: 110-121, 2008.
10. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M and Zocchi MR: Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23: 641-648, 2009.
11. Zhang C, Wang Y, Zhou Z, Zhang J and Tian Z: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58: 1275-1285, 2009.
12. Imai T, Adachi S, Nishijo K, et al: FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22: 9231-9242, 2003.
13. Yamanegi K, Yamane J, Hata M, et al: Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. J Cancer Res Clin Oncol 135: 879-889, 2009.
14. Watanabe K, Okamoto K and Yonehara S: Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12: 10-18, 2005.
15. Johannessen CU and Johannessen SI: Valproate: past, present, and future. CNS Drug Rev 9: 199-216, 2003.
16. Allen MH, Hirschfeld RM, Wozniak PJ, Baker JD and Bowden CL: Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 163: 272-275, 2006.
17. Kaiser BK, Yim D, Chow IT, et al: Disulphide-isomerase-enabled shedding of tumor-associated NKG2D kigands. Nature 447: 482-486, 2007. (Pubitemid 46816733)
18. Fuertes MB, Girart MV, Molinero LL, et al: Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 180: 4606-4614, 2008.